Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer

Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer
Women with BRCA-mutated relapsed serous ovarian cancer who received AstraZeneca’s Lynparza (olaparib) as a maintenance therapy after responding to platinum-based chemotherapy took an average 14 months to see their disease progress, compared to 7.3 months among patients receiving placebo. Additionally, the quality of life (QoL) in the two groups was similar, according to ratings by the patients. The results

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *